Shots:
- Merck KgaA provides an update on its P-III INTR@PID Lung 037 study and the extensive INTR@PID clinical trial program assessing bintrafusp alfa for patients with BTC and cervical cancer
- Based on the IDMC’s recommendation, Merck will discontinue the INTR@PID Lung 037 study as it fails to meet its co-1EPs, specifically PFS. The ongoing clinical trial INTR@PID Lung 037 includes 1L treatment of patients with stage IV NSCLS having PD-L1 expression
- The company will further evaluate bintrafusp alfa in other studies. GSK has high hopes with the drug as it has paid $4.2B+ in the collaboration signed in 2019
Click here to read full press release/ article | Ref: Merck KgaA | Image: GMP News
The post Merck KGaA and GSK’s Bintrafusp Alfa Fails to Meet its Co-Primary Endpoints in Lung Cancer Study first appeared on PharmaShots.
